Dr Georgios Imseeh

Job title

Consultant clinical oncologist

Contact details

Email: northmid.oncologysecs@nhs.net

Lung

Tel: 020 8887 2284

Urology

Tel: 020 8887 3061

Related services

Cancer services

Location

North Middlesex University Hospital

Biography

Dr Georgios (George) Imseeh MRCP FRCR MD(Res) is a consultant clinical oncologist specialising in lung, prostate and bladder cancer.

He undertook his specialist training at Imperial College Healthcare NHS Trust, St Luke’s cancer centre and the Royal Marsden Hospital. As an NIHR Fellow at the institute of cancerresearch he was awarded his research degree investigating novel therapeutic approaches to treat recurrent pelvic tumours with high intensity focused ultrasound (HIFU) and stereotactic radiotherapy (SABR). He is the principal investigator for multiple international radiotherapy and systemic trials.

Dr Imseeh is passionate and deeply committed to medical education and training. He is the royal college of radiologists college tutor for oncology trainees at North Middlesex University Hospital ensuring high quality postgraduate training. Additionally, he is an honorary clinical lecturer at UCL medical school leading undergraduate oncology education at North Mid, and lectures for the MSc programme at the institute of cancer research.

GMC number

7044566

  • Determining Patterns of Relapse Following Pelvic Exenteration for Centrally Recurrent Gynecological Cancer: The Feasibility of Postoperative Stereotactic Radiotherapy. Nana Gomes, Georgios Imseeh, Desmond Patrick Barton, Nandita M. deSouza, Owen Heath, Xin Constance Du, Ayoma Attygalle, Katherine Vroobel, and Alexandra Taylor. Journal of Gynecologic Surgery. Volume 40, Number 6, November 2024 .DOI: 10.1089/gyn.2023.0139
  • Bilateral Diffuse Uveal Melanocytic Proliferation (BDUMP) associated with adenocarcinoma of the prostate. Allon G, Zhi Heng L, Imseeh G, da Cruz L, Yeung IYL.  J Fr Ophtalmol. 2023 Nov;46(9):e306-e307. doi: 10.1016/j.jfo.2023.02.009. Epub 2023 Jul 20. PMID: 37481447.
  • Patient information videos on SACT to improve patient experience and access to information: A North/NE London collaboration. Vaidehi Konteti, Ikttesh Chahal, Girija Anand, Hafza Abdirahman, Monica Castro, Shalini Fernando, Henna Fokeerbaccus, Juliana Gyamfi, Angus Hubbard, Georgios Imseeh et al.  Clinical Oncology Volume 34 Pages e11-e12 (November 2022), DOI: 10.1016/j.clon.2022.09.022
  • Feasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease. Imseeh G, Giles SL, Taylor A, Brown MRD, Rivens I, Gordon-Williams R, Ter Haar G, deSouza NM.  Int J Hyperthermia. 2021;38(1):623-632. doi: 10.1080/02656736.2021.1904154. PMID: 33882792.
  • An Inter-observer Study to Determine Radiotherapy Planning Target Volumes for Recurrent Gynaecological Cancer Comparing Magnetic Resonance Imaging Only With Computed Tomography-Magnetic Resonance Imaging. Bernstein D, Taylor A, Nill S, Imseeh G, et al.  Clin Oncol (R Coll Radiol). 2021 May;33(5):307-313. doi: 10.1016/j.clon.2021.02.003. Epub 2021 Feb 25. PMID: 33640196; PMCID: PMC8051139.
  • Magnetic Resonance guided high intensity focused ultrasound for treating recurrent gynaecological tumors: effect of pre-focal tissue characteristics on target heating. Giles SL, Rivens I, Imseeh G, et al.  J Imaging Interv Radiol. 2020;3:1–10.
  • Cervical Cancer, Treatment of Cancer, 7th Edition (2020)
  • Co-author of book chapter in 7th Edition of the Treatment of Cancer.
  • MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study. Giles SL, Imseeh G, Rivens I, Ter Haar GR, Taylor A, deSouza NM.  Br J Radiol. 2019 Jun;92(1098):20181037. doi: 10.1259/bjr.20181037. Epub 2019 May 14.
  • Feasibility of post-operative stereotactic ablative radiotherapy (SABR) using cyberknife for positive margins after pelvic exenteration for gynaecological malignancy. Imseeh, G., Barton, D., Llewelyn, M., Ash, J., Fernandes, A., & Taylor, A. (2019).  International Journal of Gynecological Cancer, 29(Suppl 4), A120–A120. https://doi.org/10.1136/ijgc-2019-ESGO.166
  • Feasibility of High Dose Hypofractionated Radiotherapy in Older Patients with Gynaecological Cancer. Imseeh, G., & Taylor, A. (2018).  Radiotherapy and Oncology, 127, S897–S897.  https://doi.org/10.1016/S0167-8140(18)31979-0
  • Uterine carcinosarcoma: a retrospective clinical cohort analysis. C. Perna, G. Eminowicz, U. Asghar, G. Imseeh, A. Kirkwood, A. Mitra, R. Arora, R.S. Kristeleit.  Int J Women’s Health Care (2018), Volume 3 (1).
  • Clinical outcomes and predicting early death in early phase trials: The NIHR UCLH clinical research facility (CRF) experience. Brown, N. F., Ganguli, S., Kirkwood, A., Imseeh, G., Kristeleit, R. S., Forster, M., & Meyer, T. (2016).  Annals of Oncology, 27, vi129–vi129. https://doi.org/10.1093/annonc/mdw368.46

Dr Imseeh’s research interests include the treatment of lung, prostate and bladder cancer with advanced radiotherapy techniques and systemic therapy.